CORDIS
EU research results

CORDIS

English EN

A new vaccine strategy against serogroup b meningococcal infection: from antigen discovery to clinical trials

Project information

Grant agreement ID: QLK2-CT-1999-00359

  • Start date

    1 February 2000

  • End date

    1 April 2003

Funded under:

FP5-LIFE QUALITY

  • Overall budget:

    € 3 687 024

  • EU contribution

    € 2 640 000

Coordinated by:

GLAXOSMITHKLINE BIOLOGICALS SA

Belgium

Objective

The aim of this proposal is to design a new vaccine strategy to prevent endemic sero- group B meningococcal infections. Previous strategies using outer membrane vesicles(OMV) purified from epidemic strains have been successful but remained limited to epidemic be- cause the immune response was restricted to strains homologous to that used to prepare the vaccine. In this proposal, we will develop an OMV vaccine using a genetically modified serogroup B strain to express high amount of an antigen that induces bactericidal antibodies against a wide range of MenB strains. This new vaccine wills
(i)benefit from the proven technology of using an OMV vaccine that presents the native antigen in outer membrane, and
(ii)improve that technology by including antigens that are efficient against a wide range of strains. This proposal encompass two major parts.
(i) The identification of outer membrane component(s)that are suitable for over expression in the vaccine strain
(ii)The over expression of successful candidates in the suitable strain. The recombinant bacteria will be used to produce OMVs and the OMV will be tested in human volunteers.

Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

GLAXOSMITHKLINE BIOLOGICALS SA

Address

Rue De L'Institut 89
--- Rixensart

Belgium

Participants (8)

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France

KAROLINSKA INSTITUTE

Sweden

MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V.

Germany

MICROBIOLOGICAL RESEARCH AUTHORITY

United Kingdom

NATIONAL BIOLOGICAL STANDARDS BOARD

United Kingdom

NORWEGIAN INSTITUTE OF PUBLIC HEALTH

Norway

THE NATIONAL HOSPITAL UNIVERSITY OF OSLO

Norway

WISE & MUNRO LEARNING RESEARCH

Netherlands

Project information

Grant agreement ID: QLK2-CT-1999-00359

  • Start date

    1 February 2000

  • End date

    1 April 2003

Funded under:

FP5-LIFE QUALITY

  • Overall budget:

    € 3 687 024

  • EU contribution

    € 2 640 000

Coordinated by:

GLAXOSMITHKLINE BIOLOGICALS SA

Belgium